3 Australian Penny Stocks Backed By Profits Revenue Or Cash Flow

Euro Area manufacturing is now described as the strongest in four years, which puts the spotlight back on smaller companies that may benefit if growth holds up. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for lower priced stocks that still focus on financial health. This article highlights three candidates from the screener that investors may want to review more closely.

The penny stocks featured below are just a starting sample from this idea, and the full screen surfaced around 400 more companies with similarly compelling financial stories that are not covered here. To identify and analyze your own highest conviction setups from this group, head straight into the Financially Fit Penny Stocks screener.

Alkane Resources is an Australian gold exploration and production company backed by real mining assets, including the Tomingley Gold Mine that generates measurable revenue and cash flow, which fits neatly with the Financially Fit Penny Stocks theme. The company also explores for copper, nickel, zinc, and silver and invests in junior gold projects, so not all activity is tied to current production. Alkane Resources has a market cap of about A$2.45b, which places it at the larger end of the penny and smaller company universe while still trading at a lower share price.

Alkane Resources combines a producing gold portfolio with record FY26 profit of A$228.7 million and a maiden fully franked dividend, which is unusual for a company still priced in penny stock territory. The core interest is Tomingley and the broader multi mine platform that is already generating solid margins, supported by a P/E that sits below the Australian metals and mining average and a high 20.5% ROE. On the risk side, you are dealing with underground mining complexity, external borrowing rather than customer funding, and a board that is still bedding down after the Mandalay merger. For investors who are interested in a financially focused gold producer with both current cash returns and longer term optionality, Alkane Resources may warrant a closer look.

Alkane Resources combines a producing gold mine, strong FY26 profit and a maiden dividend. However, the full story may not be obvious from headline figures. Get the full context in the analysis report for Alkane Resources

Build your own shortlist of financially fit penny stocks

Alkane Resources and the other two stocks in this article are all examples of what can appear when you filter for financial strength instead of just a low share price. Use our customisable Screener to combine valuation, growth, balance sheet and dividend filters into something that suits your style, or browse our ready made Investing Ideas for curated starting points.

Sigma Healthcare is a long established Australian pharmacy group that franchises retail brands like Chemist Warehouse, Amcal and Discount Drug while running a large pharmaceutical wholesale and distribution network that supplies community pharmacies and provides third and fourth party logistics services to drug manufacturers. That wholesale and logistics engine is the clearest link to the Financially Fit Penny Stocks theme, since it is an operational, revenue generating business that underpins the group’s financial profile. Sigma reports about A$9.55b of revenue from its Healthcare segment and has a market cap of roughly A$33.36b, which places it well beyond the smallest end of the penny stock universe but still trading at a lower share price.

Investors looking at Sigma Healthcare are really weighing the appeal of a pharmacy wholesale and logistics platform that supports community pharmacies against a few clear pressure points. On one side, Sigma has grown earnings strongly over the last five years and still carries “high quality earnings,” with revenue and earnings forecasts that edge ahead of the broader Australian market and a focus on its Australian base after stepping away from the Boots UK deal. On the other side, profit margins have slipped from 11.5% to 6.3%, the stock trades on a rich P/E for this sector, and the balance sheet leans on higher risk external borrowing, all under a relatively new board. The mix of stable wholesale cash flows, growth potential and these governance and funding questions is what makes Sigma worth a closer second look.

Sigma Healthcare’s earnings engine and rich P/E are pulling in different directions, which is exactly what makes the next move so interesting. Get the fuller story in the 2 key rewards and 1 important warning sign

Mesoblast is a Melbourne based biotech that develops cell based regenerative medicines, including Remestemcel L and a pipeline of MPC therapies targeting severe inflammatory and cardiovascular conditions. Its business is still concentrated in building out this technology platform for commercialization, which generated about US$65 million of revenue, and aligns closely with the Financially Fit Penny Stocks theme of earlier stage products carried by smaller cap, sub 5 stocks. Mesoblast has a market cap of roughly A$3.07b, reflecting investor interest in its late stage clinical programs and existing product sales.

Mesoblast offers a combination of an already launched product in Ryoncil with triple digit million US dollar revenues and multiple Phase III programs in large markets such as chronic low back pain and heart failure. At the same time, the company is still loss making, carries funding risk through external borrowing and needs positive trial readouts and regulatory decisions over the next few years to support its growth story. For investors considering higher risk biotech within a financially focused penny stock universe, Mesoblast’s mix of existing revenues, broad patent estate and upcoming trial milestones may warrant closer study.

Mesoblast’s late stage pipeline and existing revenue stream often get all the attention, yet the real story may be how consensus sees the next phase unfolding. Get the analyst forecasts for Mesoblast and what might be missing from that outlook.

Seeking Alternatives Beyond Your Current Watchlist

Fresh opportunities can move from quiet to breakout quickly, and laggards can keep dropping once the crowd catches on. Scan these under the radar ideas while it matters and get in early.

• Spot companies quietly building momentum before headlines catch up when you run the 11 high quality undiscovered gems and focus on stronger balance sheets instead of hype driven stories.
• Target cash rich businesses that may handle shocks better by scanning the list of solid balance sheet and fundamentals (20 results) and filtering for fundamentals that support resilience, not just share price moves.
• Consider potential income and price momentum together by checking the 6 dividend fortresses and focusing on companies that pair higher yields with disciplined financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com